SCNI
Scinai Immunotherapeutics LtdKey Statistics
About Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd is an innovative biotechnology firm at the forefront of developing advanced immunotherapy solutions, particularly targeting cancer and autoimmune disorders. Leveraging its proprietary immune modulation platform, Scinai is advancing a promising clinical pipeline designed to deliver transformative therapies that enhance patient outcomes. Guided by a seasoned leadership team with extensive expertise in immunology and drug development, the company is poised to capitalize on the burgeoning demand for groundbreaking immunotherapeutics in the global healthcare market. Scinai's commitment to rigorous research and strategic partnerships further positions it for significant growth and impact within the biopharmaceutical industry.
Fundamentals
| Revenue (TTM) | $1.31M |
| Gross Profit (TTM) | $-2.65M |
| EBITDA | $-6.12M |
| Operating Margin | -702.00% |
| Return on Equity | -91.90% |
| Return on Assets | -37.60% |
| Revenue/Share (TTM) | $0.56 |
| Book Value | $1.47 |
| Price-to-Book | 0.84 |
| Price-to-Sales (TTM) | 1.56 |
| EV/Revenue | 6.34 |
| EV/EBITDA | 1.13 |
| Quarterly Earnings Growth (YoY) | 87.20% |
| Quarterly Revenue Growth (YoY) | 30.60% |
| Shares Outstanding | $3.54M |
| Float | $12.25B |
| % Insiders | 11.37% |
| % Institutions | 5.13% |